These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35247148)

  • 21. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy].
    Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A multi-factorial analysis of response to warfarin in a UK prospective cohort.
    Bourgeois S; Jorgensen A; Zhang EJ; Hanson A; Gillman MS; Bumpstead S; Toh CH; Williamson P; Daly AK; Kamali F; Deloukas P; Pirmohamed M
    Genome Med; 2016 Jan; 8(1):2. PubMed ID: 26739746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Warfarin pharmacogenetics: a controlled dose-response study in healthy subjects.
    Kadian-Dodov DL; van der Zee SA; Scott SA; Peter I; Martis S; Doheny DO; Rothlauf EB; Lubitz SA; Desnick RJ; Halperin JL
    Vasc Med; 2013 Oct; 18(5):290-7. PubMed ID: 24029542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extremely low therapeutic doses of acenocoumarol in a patient with
    Chaidaroglou A; Kanellopoulou T; Panopoulos G; Stavridis G; Degiannis D
    Pharmacogenomics; 2019 Apr; 20(5):311-317. PubMed ID: 30983536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes: comment.
    Gaikwad T; Ghosh K; Shetty S
    J Thromb Haemost; 2017 Aug; 15(8):1708. PubMed ID: 28608988
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical Application of Genotype-guided Dosing of Warfarin in Patients with Acute Stroke.
    Šupe S; Poljaković Z; Božina T; Ljevak J; Macolić Šarinić V; Božina N
    Arch Med Res; 2015 May; 46(4):265-73. PubMed ID: 25989350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
    J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Warfarin pharmacogenetics.
    Johnson JA; Cavallari LH
    Trends Cardiovasc Med; 2015 Jan; 25(1):33-41. PubMed ID: 25282448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Warfarin dosing algorithms: A systematic review.
    Asiimwe IG; Zhang EJ; Osanlou R; Jorgensen AL; Pirmohamed M
    Br J Clin Pharmacol; 2021 Apr; 87(4):1717-1729. PubMed ID: 33080066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism.
    Vandell AG; Walker J; Brown KS; Zhang G; Lin M; Grosso MA; Mercuri MF
    Heart; 2017 Nov; 103(22):1800-1805. PubMed ID: 28689179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon.
    Verhoef TI; Redekop WK; Daly AK; van Schie RM; de Boer A; Maitland-van der Zee AH
    Br J Clin Pharmacol; 2014 Apr; 77(4):626-41. PubMed ID: 23919835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Genotype-Guided Warfarin Dosing in the Chinese Population: A Meta-analysis of Randomized Controlled Trials.
    Wang F; Guo J; Zhang A
    J Cardiovasc Pharmacol; 2019 Mar; 73(3):127-135. PubMed ID: 30688796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.
    Sconce EA; Khan TI; Wynne HA; Avery P; Monkhouse L; King BP; Wood P; Kesteven P; Daly AK; Kamali F
    Blood; 2005 Oct; 106(7):2329-33. PubMed ID: 15947090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genes affecting warfarin response-interactive or additive?
    Cavallari LH; Duarte JD
    J Clin Pharmacol; 2015 Mar; 55(3):258-60. PubMed ID: 25385663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Implementing Algorithm-Guided Warfarin Dosing in an Ethnically Diverse Patient Population Using Electronic Health Records and Preemptive CYP2C9 and VKORC1 Genetic Testing.
    Obeng AO; Kaszemacher T; Abul-Husn NS; Gottesman O; Vega A; Waite E; Myers K; Cho J; Bottinger EP; Ellis SB; Scott SA
    Clin Pharmacol Ther; 2016 Nov; 100(5):427-430. PubMed ID: 27393744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of genetic and patient factors on warfarin pharmacodynamics following warfarin withdrawal: Implications for patients undergoing surgery.
    Abohelaika S; Wynne H; Avery P; Kampouraki E; Kamali F
    Thromb Res; 2018 Nov; 171():167-170. PubMed ID: 30321703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic and clinical determinants influencing warfarin dosing in children with heart disease.
    Nguyen N; Anley P; Yu MY; Zhang G; Thompson AA; Jennings LJ
    Pediatr Cardiol; 2013 Apr; 34(4):984-90. PubMed ID: 23183958
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A pharmacogenetic versus a clinical algorithm for warfarin dosing.
    Kimmel SE; French B; Kasner SE; Johnson JA; Anderson JL; Gage BF; Rosenberg YD; Eby CS; Madigan RA; McBane RB; Abdel-Rahman SZ; Stevens SM; Yale S; Mohler ER; Fang MC; Shah V; Horenstein RB; Limdi NA; Muldowney JA; Gujral J; Delafontaine P; Desnick RJ; Ortel TL; Billett HH; Pendleton RC; Geller NL; Halperin JL; Goldhaber SZ; Caldwell MD; Califf RM; Ellenberg JH;
    N Engl J Med; 2013 Dec; 369(24):2283-93. PubMed ID: 24251361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between genetic polymorphisms of CYP2C9 and VKORC1 and safety and efficacy of warfarin: Results of a 5 years audit.
    Biswas M; Bendkhale SR; Deshpande SP; Thaker SJ; Kulkarni DV; Bhatia SJ; Rajadhyaksha AG; Gogtay NJ; Thatte UM
    Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S13-S19. PubMed ID: 30595245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacogenetic-guided and clinical warfarin dosing algorithm assessments with bleeding outcomes risk-stratified by genetic and covariate subgroups.
    Dietz N; Ruff C; Giugliano RP; Mercuri MF; Antman EM
    Int J Cardiol; 2020 Oct; 317():159-166. PubMed ID: 32505370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.